CapsoVision, Inc (NASDAQ: CV)

CapsoVision, Inc is a commercial-stage medical technology company specializing in diagnostic and screening products for gastrointestinal tract abnormalities. Founded in 2005 and headquartered in Saratoga, California, the company develops advanced imaging and artificial intelligence technologies to enhance the flexibility, convenience, and safety of patient care. Its flagship solution, the CapsoCam capsule endoscopy system, includes single-use ingestible capsules and associated software platforms, CapsoCloud and CapsoView, designed to visualize and detect pathologies in the small bowel and colon.

CapsoVision generates revenue primarily through the sale of its CapsoCam Plus capsules, which are used for small bowel visualization in adults and children aged two years and above. The company markets these capsules directly to gastroenterologists practicing in clinics and hospitals, as well as through distributors in international markets. In 2025, CapsoVision reported approximately 15% year-over-year revenue growth, reaching 13.6 million dollars, driven by an increase in capsule sales. The company also anticipates future revenue streams from its pipeline product, CapsoCam Colon, pending regulatory clearance, which targets colon polyp detection and measurement.

The company operates through the following segments:

• Small Bowel Capsule Endoscopy: This segment centers on the CapsoCam Plus capsule, which captures a 360-degree panoramic video of the small bowel mucosa to detect abnormalities such as obscure gastrointestinal bleeding, Crohn’s disease, and tumors. The system includes onboard memory for wire-free data storage and cloud-based software for remote video review and analysis. CapsoVision has sold over 161,000 CapsoCam Plus capsules as of December 2025, with ongoing enhancements, including AI-assisted pathology detection, expected to further improve diagnostic yield and clinician efficiency.

• Colon Capsule Endoscopy: This segment focuses on the CapsoCam Colon capsule, currently in development, which aims to visualize the colon and detect polyps using AI and proprietary 3D-sensing technology. The capsule is designed to provide a panoramic view of the colon, automate polyp detection, and measure polyp size to inform follow-up care decisions. CapsoVision submitted a 510(k) application for the second-generation CapsoCam Colon in 2026, targeting FDA clearance and subsequent commercialization in the U. S. and European markets.

CapsoVision holds a distinctive position in the capsule endoscopy market, competing with established players such as Medtronic, IntroMedic, and Ankon. Its primary competitive advantage lies in the CapsoCam system’s 360-degree panoramic imaging, which provides superior diagnostic yield compared to competitors’ end-view systems. The company’s wire-free, zero-capital-expenditure solution eliminates the need for external data recorders, enhancing clinical workflow efficiency and patient comfort. Additionally, CapsoVision’s proprietary AI and 3D-sensing technologies, once fully integrated, are expected to further differentiate its products by improving diagnostic accuracy and reducing clinician review time. The company’s intellectual property portfolio, comprising over 140 issued patents, strengthens its market position and protects its innovations.

CapsoVision serves a customer base primarily composed of gastroenterologists operating in clinics and hospitals. In the U. S., the company sells directly through an in-house sales team, while international sales are facilitated through a network of approximately 55 exclusive distributors across Europe, Asia, South and Central America, Australia, the Middle East, and Africa. Key international markets include France, Germany, and Canada, which collectively accounted for a significant portion of the company’s non-U. S. revenue in 2025. CapsoVision also maintains a high customer retention rate, reflecting its focus on customer satisfaction and product reliability.